The University of Kentucky’s Center for Clinical and Translational Science has received nearly $40 million from the National Institutes of Health (NIH) to support various health initiatives. This funding is part of a broader effort to enhance the translation of scientific discoveries into practical treatments.
Dr. Philip Kern, co-director of the center, highlighted the crucial role of funding in the development of medications. He noted that while pharmaceutical companies manufacture drugs, the foundational research needed for these developments stems from NIH-funded studies. “These drugs are manufactured by a drug company, but the discoveries all came from the NIH-funded research,” Kern explained during a recent event.
Since 2011, the center has received nearly $100 million in funding from the NIH. It is among just 65 institutions nationwide that hold this prestigious award. Of those, Kentucky’s center is one of 34 that also focuses on translational science, cancer, and Alzheimer’s disease.
The new funds will be allocated to various projects, including the implementation of same-day testing and treatment for hepatitis C in Appalachian counties. Additionally, the funding will help expand the university’s biomedical informatics and data science programs, as well as its biospecimen bank, establishing a network aimed at identifying genetic factors associated with diseases.
This substantial investment signifies continued support for innovative research and healthcare advancements in Kentucky and the surrounding regions.
